SMi Group Release Exclusive Interview with Takeda in the Run-Up to ADMET 2016
SMi’s 11th annual ADMET conference returns to London this June and is thrilled to have Pau Aceves, Senior Clinical Pharmacologist from Takeda UK as one of the featured speakers for 2016.
London, United Kingdom, May 23, 2016 --(PR.com)-- Pau has been involved in a number of rare disease programs where he has found PK/PD modelling, and in particular PBPK, to be of assistance when dealing with some of the inherit complexities and questions that arise during the development of drugs in these type of rare or ultra-rare populations.
His opening keynote entitled: "Application of PBPK to Drug Development in Rare Diseases," will explore clinical drug development in rare diseases, discuss key issues surrounding clinical trials and patient recruitment, as well as provide case study examples on how PBPK modelling can facilitate the conduct of clinical trials.
In the run-up to his address, SMi Group caught up with Pau to discuss his presentation and current industry challenges.
When asked how he would describe current trends ADME and toxicology testing, he said:
“Currently, the way in which preclinical ADME data are presented to drug development project teams is generally geared towards the more frequently studied types of patient populations; however further considerations may apply to other more complex populations. This is for example the case in certain rare diseases where the use of concomitant medications may include drugs with Narrow Therapeutic Index and/or multi-pathway inhibitors which need to be taken into consideration to assess the actual risk of drug-drug interaction.”
On his upcoming presentation he commented:
“My presentation will focus on a case example were a drug that was predicted to have a low drug-drug interaction potential based on in vitro data in an oncology population, had a higher unanticipated risk when repurposed for a new rare disease indication, and how a Physiologically-Based Pharmacokinetic modelling strategy was devised to enable a safer conduct of a first-in-disease clinical trial. The presentation will also touch on published work relating to PBPK modelling as applied to rare disease indications.”
The full interview is available to read in the event download centre at www.admet-event.com
Other notable speakers on the agenda include: Genentech, Merck Serono, GSK, Sanofi-Aventis, Roche, Lundbeck and Imperial College London.
11th Annual ADMET Conference
13TH – 14TH June 2016
Holiday Inn Kensington Forum, London UK
www.admet-event.com
Sponsored by Corning Incorporated and Sekisui XenoTech
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
His opening keynote entitled: "Application of PBPK to Drug Development in Rare Diseases," will explore clinical drug development in rare diseases, discuss key issues surrounding clinical trials and patient recruitment, as well as provide case study examples on how PBPK modelling can facilitate the conduct of clinical trials.
In the run-up to his address, SMi Group caught up with Pau to discuss his presentation and current industry challenges.
When asked how he would describe current trends ADME and toxicology testing, he said:
“Currently, the way in which preclinical ADME data are presented to drug development project teams is generally geared towards the more frequently studied types of patient populations; however further considerations may apply to other more complex populations. This is for example the case in certain rare diseases where the use of concomitant medications may include drugs with Narrow Therapeutic Index and/or multi-pathway inhibitors which need to be taken into consideration to assess the actual risk of drug-drug interaction.”
On his upcoming presentation he commented:
“My presentation will focus on a case example were a drug that was predicted to have a low drug-drug interaction potential based on in vitro data in an oncology population, had a higher unanticipated risk when repurposed for a new rare disease indication, and how a Physiologically-Based Pharmacokinetic modelling strategy was devised to enable a safer conduct of a first-in-disease clinical trial. The presentation will also touch on published work relating to PBPK modelling as applied to rare disease indications.”
The full interview is available to read in the event download centre at www.admet-event.com
Other notable speakers on the agenda include: Genentech, Merck Serono, GSK, Sanofi-Aventis, Roche, Lundbeck and Imperial College London.
11th Annual ADMET Conference
13TH – 14TH June 2016
Holiday Inn Kensington Forum, London UK
www.admet-event.com
Sponsored by Corning Incorporated and Sekisui XenoTech
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Teri Arri
+44 20 7827 6138
http://www.admet-event.com
Teri Arri
+44 20 7827 6138
http://www.admet-event.com
Contact
Categories